ENDRA's TAEUS Demonstrates Strong Consistency in Clinical Evaluation; Stock Gains

ENDRA Life Sciences Inc. (NDRA) has unveiled clinical research findings that reinforce the reliability of its TAEUS Liver technology for measuring hepatic fat content in point-of-care settings. The breakthrough suggests that consistency—a critical factor in diagnostic device performance—positions the platform favorably against existing diagnostic methods. Across a rigorously controlled evaluation involving 14 participants and 56 individual measurements performed by different clinicians, the TAEUS system maintained exceptional reproducibility with an intraclass correlation coefficient of 0.89, a figure indicating strong inter-operator reliability.

Reliability and Consistency at the Core

The clinical data highlights why consistency matters in practical healthcare settings. The device recorded a standard error of measurement of just 3.3%, demonstrating that repeated measurements yield stable, dependable results regardless of the clinician operating the system. This reproducibility is particularly significant for diseases requiring frequent monitoring, such as metabolic dysfunction-associated steatotic liver disease, which affects approximately 30% of the global adult population. By delivering consistent measurements with minimal operator variability, TAEUS addresses a long-standing challenge in non-invasive liver fat assessment.

Advantages Over Traditional Imaging Methods

ENDRA positions TAEUS as a cost-effective alternative to MRI imaging, which remains the gold standard for liver fat quantification but suffers from accessibility constraints and high expenses. Traditional ultrasound methods, meanwhile, are known for substantial operator-dependent variation that can undermine diagnostic confidence. The clinical consistency demonstrated by TAEUS suggests it could bridge this gap—providing MRI-level reliability in everyday clinical environments without the associated costs or logistics barriers. This differentiation has drawn favorable recognition from the medical community, where consistency quotes emphasizing the device’s dependable performance have circulated among healthcare professionals evaluating advanced diagnostic solutions.

Expanding Clinical Applications and Market Potential

Beyond routine clinical monitoring, TAEUS has captured the attention of pharmaceutical developers seeking reliable patient stratification and follow-up tools for liver-related therapeutic trials. The device’s proven consistency makes it an attractive option for researchers requiring standardized measurements across diverse clinical sites. ENDRA’s market positioning reflects growing demand for accessible, reproducible diagnostic technologies that can function within standard healthcare infrastructure.

The stock market has responded positively to these developments. NDRA has traded within a range of $2.90 to $11.96 over the past 12 months, with shares currently valued at $4, representing a 7% gain. The positive reception underscores investor confidence in the company’s ability to capture market share in the point-of-care diagnostics sector.